Dihydroartemisinin/Piperaquine
Author:
- 1 May 2012
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 72 (7) , 937-961
Abstract
Artemisinin-based combination regimens are recommended by WHO for the treatment of uncomplicated Plasmodium falciparum malaria. One such combination comprises the artemisinin derivative dihydroartemisinin and the bisquinolone piperaquine. Eurartesim® is the only dihydroartemisinin/piperaquine formulation that meets international good manufacturing practice standards. This article reviews the pharmacological properties of dihydroartemisinin and piperaquine, and the therapeutic efficacy and tolerability of dihydroartemisinin/piperaquine in the treatment of uncomplicated P. falciparum malaria. A number of trials have shown dihydroartemisinin/piperaquine to be highly effective in the treatment of uncomplicated P. falciparum malaria. Two pivotal, randomized, open-label, multicentre trials demonstrated the Eurartesim® formulation of dihydroartemisinin/piperaquine to be noninferior to artesunate plus mefloquine in children and adults in Asia and noninferior to artemether/lumefantrine in children in Africa, in terms of polymerase chain reaction-corrected cure rates. In both trials, dihydroartemisinin/piperaquine recipients were significantly less likely than artesunate plus mefloquine recipients or artemether/lumefantrine recipients to experience reinfection. Gametocyte carriage was greater in patients receiving dihydroartemisinin/piperaquine than in those receiving comparator antimalarial regimens. The Eurartesim® formulation of dihydroartemisinin/piperaquine was generally well tolerated in the treatment of uncomplicated P. falciparum malaria, and was associated with significantly less nausea, vomiting and dizziness than artesunate plus mefloquine. Although prolongation of the corrected QT interval has been reported in patients receiving dihydroartemisinin/piperaquine, there are currently no clinical data signalling that it is associated with clinically significant arrhythmias. In conclusion, dihydroartemisinin/piperaquine is a valuable option for use in the first-line treatment of uncomplicated P. falciparum malaria.Keywords
This publication has 73 references indexed in Scilit:
- Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled TrialClinical Infectious Diseases, 2011
- Artemisinin combination therapy for vivax malariaThe Lancet Infectious Diseases, 2010
- Artemisinin Resistance inPlasmodium falciparumMalariaNew England Journal of Medicine, 2009
- A Trial of Combination Antimalarial Therapies in Children from Papua New GuineaNew England Journal of Medicine, 2008
- Evidence of Artemisinin-Resistant Malaria in Western CambodiaNew England Journal of Medicine, 2008
- Adverse Pregnancy Outcomes in an Area Where Multidrug‐ResistantPlasmodium vivaxandPlasmodium falciparumInfections Are EndemicClinical Infectious Diseases, 2008
- A randomized open study to assess the efficacy and tolerability of dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in CambodiaTropical Medicine & International Health, 2007
- In Vitro Interactions between Piperaquine, Dihydroartemisinin, and Other Conventional and Novel Antimalarial DrugsAntimicrobial Agents and Chemotherapy, 2006
- An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos)Tropical Medicine & International Health, 2006
- Artemisinins target the SERCA of Plasmodium falciparumNature, 2003